Navigation Links
Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
Date:7/25/2012

FORT WORTH, Texas, July 25, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that the results of a 24-week open-label follow-up to the HP802-247 Phase 2b trial will be presented by Robert Kirsner, MD, PhD, on Friday, July 27, 2012, from 3:55-4:15 pm, during the American College of Wound Healing and Tissue Repair held at the Swissotel in Chicago. HP802-247 is an allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently being investigated for the treatment of venous leg ulcers.

Venous leg ulcers affect approximately 2.5 million Americans and are associated with impaired circulation most commonly resulting from damaged veins and/or valves. They typically appear as an open lesion, or ulcer, on the lower extremities, are very slow to heal and often reoccur due to the chronic nature of the underlying disease process.

The Phase 2b trial was designed to determine the potential effectiveness of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care, compared to control plus standard care, in healing venous leg ulcers over a 12-week treatment period. The study was a randomized, double blind, dose-finding study involving 228 subjects enrolled across 35 investigational centers in the United States. Overall, HP802-247 achieved statistical significance, as compared with control plus standard care, in both the primary and secondary endpoints. HP802-247 was generally well tolerated in the study with the most frequently reported adverse events being skin ulcers, cellulitis, wound infection and skin irritation.  The safety profile of the active groups was similar to the vehicle control.

The 24-week open-label extension of this Phase 2b trial was designed to evaluate the status of the target wound (e.g., open, re-opened or healed), as well as the status of the periwound area following the 12-week treatment period. HP802-247 was not administered to patients durin
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
2. Robert Farrell Joins Bionovos Board of Directors
3. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
4. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
7. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
10. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
11. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  The full interim results will be presented ... and IGF Society, being held October 15-18, 2014, ...
(Date:9/16/2014)... September 16, 2014 BCC Research ... FOR STEM CELLS , the global market for stem ... by 2018, with a five-year compound annual growth rate ... in the Americas with growth projections of $2.2 billion ...      (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential ...
(Date:9/16/2014)... 2014 RENU 28, the world's first and ... available for purchase in Australia and New Zealand in mid-August ... September 16th. The tour will make stops in Brisbane on ... the 18th, Sydney on the 20th, and Melbourne on the ... New Zealand and to educate people about the new product ...
(Date:9/15/2014)... , Sept. 15, 2014   Global Science ... of scientific products and services for satellite and ... Solution for Integrated Services (OASIS) from the General ... was selected to provide the government best-value solutions ... Business (SB) category in Pool 4. The OASIS ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... Biomerica,Inc. (OTC Bulletin Board: BMRA) has introduced a ... announced that it received CE mark approval to,market and ... in,the European Union. The product will be marketed under ... people in the U.S. are allergic to cat dander,the ...
... 18 Forest Laboratories, Inc.,(NYSE: FRX ) and ... the novel beta,blocker Bystolic(TM) (nebivolol) was approved by the ... hypertension. Bystolic is a once,daily medication that can be ... affects approximately 72 million,adults in the U.S. and 65 ...
... Using the latest methods for nanofabrication, a team led ... electronic property in one of the earliest-known and most-studied ... magnetite. , By changing the voltage in their experiment, ... than minus 250 degrees Fahrenheit to revert from an ...
Cached Biology Technology:Biomerica Introduces a New 15 Minute Home Test for Allergies to Cats and Receives CE Mark Approval for Home Use 2Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 2Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 3Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 4Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 5New property found in ancient mineral lodestone 2
(Date:9/16/2014)... is associated with increased rates and intensity of tobacco ... the relationship between schizophrenia and smoking stems, in part, ... self-medicate symptoms and cognitive impairment associated with the disease. ... of Biological Psychiatry , sheds light on this ... receptors in the brain was lower in schizophrenia patients ...
(Date:9/16/2014)... responsible for practically all vital functions in an ... signals, transport particular substances and control immune system ... do not function independently of each other, but ... the protein networks, you find many similarities with ... TUM,s Chair of Plant Systems Biology. "Some proteins ...
(Date:9/15/2014)... Human skin and gut microbes influence processes from digestion ... are the most biodiverse terrestrial ecosystems on the planet, ... trees in the tropics. Smithsonian scientists and colleagues working ... samples from a single tree were home to more ... from 57 tree species contained more than 7,000 different ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2Smithsonian scientists discover tropical tree microbiome in Panama 2
... enemy of the good, but in the nanoscale world, perfection can ... world, engineers and scientists go to great lengths to make the ... a light switch or turn the key on the car, we ... every time, with only rare exceptions. They have done so by ...
... (President Ryoji Noyori) and the Max Planck Society (MPG; ... 2011, to strengthen their collaboration by ,establishing a joint ... seeks to ,achieve a systematic understanding of biological systems ... research center will bring together the RIKEN Advanced Science ...
... that parents can fill out in pediatrician waiting rooms may ... disorder (ASD) , according to a study funded by the ... of Pediatrics , the study,s design also provides a model ... change to their practice. "Beyond this exciting proof of ...
Cached Biology News:Nanotechnologists must take lessons from nature 2Nanotechnologists must take lessons from nature 35-minute screen identifies subtle signs of autism in 1-year olds 2
... clone d1-174 GenBank Accession Number : ... N-terminal tagged fusion protein corresponding to full ... Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium ... 30% Quality Assurance: routinely evaluated by immunoblot ...
...
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Biology Products: